Loading company…
Tianjin Suntech develops drug candidates for cancer stem cells and autoimmune diseases.
Founded in 2008 and based in Tianjin, China, Tianjin Suntech develops drugs for cancer stem cells and autoimmune diseases, with research centers in Australia and China. Its ACT001 candidate has orphan drug status in the US and EU, and the company has conducted clinical trials in several countries. Series C funding raised in May 2022 was intended to support clinical trials, hiring, and marketing preparation.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in